Beginning in the 1980’s, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy.
This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors.
The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors.
Compiles the results of four decades of progress
Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject. Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment. Covers specific molecular targets for inhibiting angiogenesis in cancer therapy. Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors. Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers.
This volume celebrates progress made in four decades, and more importantly, it provides a clear indication of the complex biology that needs further investigation to realize the possibilities envisioned for this beneficial therapeutic modality.
Under physiological conditions, angiogenesis is dependent on the balance of positive and negative angiogenic modulators within the vascular microenvironment and requires the functional activities of a number of molecules, including angiogenic factors, extracellular matrix proteins, adhesion molecules and proteolytic enzymes.
In normal tissues, vascular quiescence is maintained by the dominant influence of endogenous angiogenesis inhibitors over angiogenic stimuli.
Tumor angiogenesis is linked to a switch in the balance between positive and negative regulators, and mainly depends on the release by inflammatory or neoplastic cells of specific growth factors for endothelial cells, that stimulate the growth of the blood vessels of the host or the down-regulation of natural angiogenesis inhibitors.
In particular, the inflammatory infiltrate may contribute to tumor angiogenesis, and there are many reports of associations between tumor inflammatory infiltrate, vascularity and prognosis.
New therapeutic approaches have been developed with the aim to control tumor angiogenesis through targeting of different components of tumor microenvironment.
Angiogenesis is a principle that can be used to guide treatment of diseases of any organ system. Dermatology may be the first specialty to be guided by the principle of angiogenesis because the lesions are visible and response can be easily monitored. Dermatologists already inhibit angiogenesis as part of their treatment of multiple common dermatologic disorders, including acne, warts, and nonmelanoma skin cancer.
Angiogenesis in Inflammation: Mechanisms and Clinical Correlates develops current knowledge on the mechanisms at the molecular and cellular levels as they relate to inflammation, including acute and chronic inflammation, neurogenic initiation, and the role of the multiple cellular components that comprise inflammation: granulocytes, macrophages, fibroblasts, dendritic cells and lymphocytes. This is related to inflammatory diseases: not only the familiar angiogenesis dependent diseases of rheumatoid arthritis and psoriasis, but also loci such as the lung, gastric ulcers, the eye with uveitis, wound healing and periodontal disease and their therapy. The book shows how this knowledge may be used in the discovery of novel therapeutics. It brings together experts in each of these fields to link the molecular and cellular processes in angiogenesis to those of inflammation and disease, culminating in a discourse on areas for future therapies.
Angiogenesis: From Basic Science to Clinical Applications presents the latest advances in basic science and reviews the status of the clinical applications of angiogenic growth factors and inhibitors. It explores current molecular and genetic findings on the regulation of angiogenesis, discusses the results of clinical trials and identifies the pathological conditions that are most likely to benefit from such treatments.
Edited by a leading researcher in the field, the book includes contributions from multiple experts in their respective disciplines, supplemented by illustrations and photographs. A unique combination of information on basic science and clinical trials research, this book is truly a state-of-the-art review of the state of the science.
Combining Targeted Biological Agents with Radiotherapy: Current Status and Future Directions is an overview of the current state of clinical and pre-clinical research in combining radiotherapy with targeted biological agents to fight cancer. The text provides a general overview of targeted agents, reviews the current clinical trials, and includes a look at the future of this state-of-the-art practice.
This book begins with a general overview of the topic, including an introduction to the subject; the basic science rationale behind the two most important current targeted agents: epidermal growth factor (EGFR) receptors and vascular epithelial growth factor (VEGF) receptors; the dermatologic manifestations of targeted agents; and an introduction to radioimmunotherapy a treatment that has the ability to combine targeted agents directly with radiotherapy. The second half of the book focuses on specific disease sites, including malignant gliomas, head and neck, lung, pancreatic, cervical, and endometrial cancers.
Biologically targeted agents promise to be the next significant breakthrough in cancer therapy. Written by leading experts in the field, Combining Targeted Biological Agents with Radiotherapy is a comprehensive evaluation of the entire field.